Multiple sclerosis and related disordersJul 18, 2026

GLP-1 receptor drugs and their potential in multiple sclerosis: a review of laboratory and patient studies

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Jul 19, 2026

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) may have anti-inflammatory and neuroprotective properties in the context of multiple sclerosis.

Multiple sclerosis is characterized by immune-mediated damage to nerve fibers.
GLP-1RAs have shown promise in reducing inflammation and protecting nerve cells in preclinical studies.
No comprehensive review of the evidence regarding GLP-1RAs in multiple sclerosis had been conducted prior to this synthesis.

Simplified

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

0%of authors

0 of 4

authors report competing interests

4 report none

PubMed

Weekly GLP-1 Therapies Brief

You found one interesting study. We’ll send the next 7.

Get 7 new glp-1 therapies papers each week, explained in plain English with direct links to the originals.

What Lands in Your Inbox Each Week:

📚7 fresh studies
📝plain-language summaries
✅direct links to original studies
🏅top journal indicators
📅weekly delivery
🧘‍♂️always free

Recent issues from the glp-1 therapies brief

Stop the drug, regain the weight: pooled data puts the average rebound at 7%

2 days ago7 studies

The brain region that explains why blocking and activating the same receptor both cause weight loss

1 week ago7 studies

GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study

2 weeks ago7 studies

Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients

3 weeks ago7 studies

Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study

4 weeks ago7 studies

Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients

5 weeks ago7 studies

Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group

6 weeks ago8 studies

New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients

7 weeks ago7 studies

GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery

8 weeks ago7 studies

Semaglutide linked to reduced cigarette craving in 24 smokers

9 weeks ago7 studies

explore the archive

See more issues from the glp-1 therapies brief